338 related articles for article (PubMed ID: 34433069)
21. Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency.
Reifschneider A; Robinson S; van Lengerich B; Gnörich J; Logan T; Heindl S; Vogt MA; Weidinger E; Riedl L; Wind K; Zatcepin A; Pesämaa I; Haberl S; Nuscher B; Kleinberger G; Klimmt J; Götzl JK; Liesz A; Bürger K; Brendel M; Levin J; Diehl-Schmid J; Suh J; Di Paolo G; Lewcock JW; Monroe KM; Paquet D; Capell A; Haass C
EMBO J; 2022 Feb; 41(4):e109108. PubMed ID: 35019161
[TBL] [Abstract][Full Text] [Related]
22. Microglial Progranulin: Involvement in Alzheimer's Disease and Neurodegenerative Diseases.
Mendsaikhan A; Tooyama I; Walker DG
Cells; 2019 Mar; 8(3):. PubMed ID: 30862089
[TBL] [Abstract][Full Text] [Related]
23. FTLD-TDP With and Without GRN Mutations Cause Different Patterns of CA1 Pathology.
Mao Q; Zheng X; Gefen T; Rogalski E; Spencer CL; Rademakers R; Fought AJ; Kohler M; Weintraub S; Xia H; Mesulam MM; Bigio EH
J Neuropathol Exp Neurol; 2019 Sep; 78(9):844-853. PubMed ID: 31361008
[TBL] [Abstract][Full Text] [Related]
24. Elevated levels of extracellular vesicles in progranulin-deficient mice and FTD-GRN Patients.
Arrant AE; Davis SE; Vollmer RM; Murchison CF; Mobley JA; Nana AL; Spina S; Grinberg LT; Karydas AM; Miller BL; Seeley WW; Roberson ED
Ann Clin Transl Neurol; 2020 Dec; 7(12):2433-2449. PubMed ID: 33197149
[TBL] [Abstract][Full Text] [Related]
25. Discovery of small molecules that normalize the transcriptome and enhance cysteine cathepsin activity in progranulin-deficient microglia.
Telpoukhovskaia MA; Liu K; Sayed FA; Etchegaray JI; Xie M; Zhan L; Li Y; Zhou Y; Le D; Bahr BA; Bogyo M; Ding S; Gan L
Sci Rep; 2020 Aug; 10(1):13688. PubMed ID: 32792571
[TBL] [Abstract][Full Text] [Related]
26. Chemical and genetic rescue of in vivo progranulin-deficient lysosomal and autophagic defects.
Doyle JJ; Maios C; Vrancx C; Duhaime S; Chitramuthu B; Bennett HPJ; Bateman A; Parker JA
Proc Natl Acad Sci U S A; 2021 Jun; 118(25):. PubMed ID: 34140407
[TBL] [Abstract][Full Text] [Related]
27. Multi-modal proteomic characterization of lysosomal function and proteostasis in progranulin-deficient neurons.
Hasan S; Fernandopulle MS; Humble SW; Frankenfield AM; Li H; Prestil R; Johnson KR; Ryan BJ; Wade-Martins R; Ward ME; Hao L
Mol Neurodegener; 2023 Nov; 18(1):87. PubMed ID: 37974165
[TBL] [Abstract][Full Text] [Related]
28. Increased lysosomal biogenesis in activated microglia and exacerbated neuronal damage after traumatic brain injury in progranulin-deficient mice.
Tanaka Y; Matsuwaki T; Yamanouchi K; Nishihara M
Neuroscience; 2013 Oct; 250():8-19. PubMed ID: 23830905
[TBL] [Abstract][Full Text] [Related]
29. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice.
Filiano AJ; Martens LH; Young AH; Warmus BA; Zhou P; Diaz-Ramirez G; Jiao J; Zhang Z; Huang EJ; Gao FB; Farese RV; Roberson ED
J Neurosci; 2013 Mar; 33(12):5352-61. PubMed ID: 23516300
[TBL] [Abstract][Full Text] [Related]
30. Progranulin deficiency in Iba-1
Takahashi K; Nakamura S; Otsu W; Shimazawa M; Hara H
J Neuroinflammation; 2021 Jul; 18(1):164. PubMed ID: 34304733
[TBL] [Abstract][Full Text] [Related]
31. Progranulin as a therapeutic target in neurodegenerative diseases.
Rhinn H; Tatton N; McCaughey S; Kurnellas M; Rosenthal A
Trends Pharmacol Sci; 2022 Aug; 43(8):641-652. PubMed ID: 35039149
[TBL] [Abstract][Full Text] [Related]
32. Approaches to develop therapeutics to treat frontotemporal dementia.
Elia LP; Reisine T; Alijagic A; Finkbeiner S
Neuropharmacology; 2020 Apr; 166():107948. PubMed ID: 31962288
[TBL] [Abstract][Full Text] [Related]
33. Progranulin deficiency induces overactivation of WNT5A expression via TNF-α/NF-κB pathway in peripheral cells from frontotemporal dementia-linked granulin mutation carriers.
Alquézar C; de la Encarnación A; Moreno F; López de Munain A; Martín-Requero Á
J Psychiatry Neurosci; 2016 Jun; 41(4):225-39. PubMed ID: 26624524
[TBL] [Abstract][Full Text] [Related]
34. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis.
Ward ME; Chen R; Huang HY; Ludwig C; Telpoukhovskaia M; Taubes A; Boudin H; Minami SS; Reichert M; Albrecht P; Gelfand JM; Cruz-Herranz A; Cordano C; Alavi MV; Leslie S; Seeley WW; Miller BL; Bigio E; Mesulam MM; Bogyo MS; Mackenzie IR; Staropoli JF; Cotman SL; Huang EJ; Gan L; Green AJ
Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404863
[TBL] [Abstract][Full Text] [Related]
35. Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia.
Holler CJ; Taylor G; McEachin ZT; Deng Q; Watkins WJ; Hudson K; Easley CA; Hu WT; Hales CM; Rossoll W; Bassell GJ; Kukar T
Mol Neurodegener; 2016 Jun; 11(1):46. PubMed ID: 27341800
[TBL] [Abstract][Full Text] [Related]
36. Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency.
Arrant AE; Nicholson AM; Zhou X; Rademakers R; Roberson ED
Mol Neurodegener; 2018 Jun; 13(1):32. PubMed ID: 29929528
[TBL] [Abstract][Full Text] [Related]
37. Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice.
Tanaka Y; Chambers JK; Matsuwaki T; Yamanouchi K; Nishihara M
Acta Neuropathol Commun; 2014 Jul; 2():78. PubMed ID: 25022663
[TBL] [Abstract][Full Text] [Related]
38. Loss of Tmem106b exacerbates FTLD pathologies and causes motor deficits in progranulin-deficient mice.
Zhou X; Brooks M; Jiang P; Koga S; Zuberi AR; Baker MC; Parsons TM; Castanedes-Casey M; Phillips V; Librero AL; Kurti A; Fryer JD; Bu G; Lutz C; Dickson DW; Rademakers R
EMBO Rep; 2020 Oct; 21(10):e50197. PubMed ID: 32761777
[TBL] [Abstract][Full Text] [Related]
39. Loss of TMEM106B potentiates lysosomal and FTLD-like pathology in progranulin-deficient mice.
Werner G; Damme M; Schludi M; Gnörich J; Wind K; Fellerer K; Wefers B; Wurst W; Edbauer D; Brendel M; Haass C; Capell A
EMBO Rep; 2020 Oct; 21(10):e50241. PubMed ID: 32929860
[TBL] [Abstract][Full Text] [Related]
40. Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia.
Kurnellas M; Mitra A; Schwabe T; Paul R; Arrant AE; Roberson ED; Ward M; Yeh F; Long H; Rosenthal A
J Transl Med; 2023 Jun; 21(1):387. PubMed ID: 37322482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
